SHISA3, an antagonist of the Wnt/β-catenin signaling, is epigenetically silenced and its ectopic expression suppresses growth in breast cancer

PloS One
Naveed ShahzadAbdul Rauf Shakoori

Abstract

Breast cancer (BC) is the foremost cause of cancer related deaths in women globally. Currently there is a scarcity of reliable biomarkers for its early stage diagnosis and theranostics monitoring. Altered DNA methylation patterns leading to the silencing of tumor suppressor genes are considered as an important mechanism underlying tumor development and progression in various cancer types, including BC. Very recently, epigenetic silencing of SHISA3, an antagonist of β-catenin, has been reported in various types of tumor. However, the role of SHISA3 in BC has not been investigated yet. Therefore, we aimed at evaluating the contribution of SHISA3 in BC causation by analyzing its expression and methylation levels in BC cell lines (MDA-MB231, MCF-7 and BT-474) and in 103 paired BC tissue samples. The SHISA3 expression and methylation status was determined by qPCR and methylation specific PCR (MSP) respectively. The role of SHISA3 in BC tumorigenesis was evaluated by proliferation and migration assays after ectopic expression of SHISA3. The association between SHISA3 hypermethylation and clinicopathological parameters of BC patients was also studied. The downregulation of SHISA3 expression was found in three BC cell lines used and in...Continue Reading

References

Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Jan 24, 2004·Cancer Biology & Therapy·Louise R Howe, Anthony M C Brown
Jun 9, 2004·Proceedings of the National Academy of Sciences of the United States of America·Daniel R RhodesArul M Chinnaiyan
Feb 23, 2007·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·Gulisa TurashviliZdenek Kolar
May 8, 2007·Developmental Biology·Kenryo FurushimaShinichi Aizawa
Nov 23, 2007·The International Journal of Developmental Biology·Thomas A Hedge, Ivor Mason
Mar 14, 2008·The New England Journal of Medicine·Malcolm V BrockJames G Herman
Mar 13, 2009·Organogenesis·Kata Boras-Granic, John J Wysolmerski
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Jul 23, 2011·Breast Care·Sylvia H Heywang-KöbrunnerStefan Sedlacek
Jul 31, 2012·Wiley Interdisciplinary Reviews. Developmental Biology·Hector Macias, Lindsay Hinck
Jan 30, 2013·Biomedical Microdevices·Zhuo Zhang, Sunitha Nagrath
Aug 13, 2013·Cell Biochemistry and Biophysics·Shaik Mohammad NaushadVijay Kumar Kutala
Jul 19, 2014·American Journal of Respiratory and Critical Care Medicine·Chun-Chieh ChenSung-Liang Yu
Dec 23, 2014·Epigenomics·Seher Karsli-CeppiogluDominique Bernard-Gallon
May 15, 2015·Annals of Surgical Oncology·Ming-Hong TsaiYa-Chien Yang
May 12, 2016·Asian Pacific Journal of Cancer Prevention : APJCP·Mahshid GhonchehHamid Salehiniya
Jun 2, 2016·Epigenetics : Official Journal of the DNA Methylation Society·Orsolya GalambBéla Molnár
Jul 16, 2016·Cancers·Qing Cissy YuYi Arial Zeng
Mar 6, 2017·Critical Reviews in Oncology/hematology·F PerriS Pisconti
Jul 22, 2017·Science·William A FlavahanBradley E Bernstein
Aug 16, 2017·Seminars in Cancer Biology·Aniruddha ChatterjeeMichael R Eccles
May 11, 2018·Scientific Reports·Alexey Koval, Vladimir L Katanaev
Jun 8, 2018·PLoS Genetics·Angela NebbiosoLucia Altucci

❮ Previous
Next ❯

Citations

Mar 2, 2021·The Chinese Journal of Physiology·Sheng-Hui TangBing-Heng Yang
May 3, 2021·Computational Biology and Chemistry·Jeremias IvanDavid Agustriawan

❮ Previous
Next ❯

Methods Mentioned

BETA
SHISAs
SHISA
PCR
transfection
RNA-Seq
electrophoresis
SHISA3

Software Mentioned

SPSS

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.